Clinical evidence for a biological effect of epigenetically active decitabine in relapsed or progressive rhabdoid tumors
暂无分享,去创建一个
R. Siebert | J. Gerss | U. Schüller | O. Witt | P. Hauser | M. Ebinger | P. Johann | S. Hettmer | M. Frühwald | K. Kerl | M. Hasselblatt | D. Sumerauer | T. Kröncke | A. Sehested | K. Nemes | Mona Steinbügl | Stefanie Tüchert | Maria João Gil da Costa | H. Reinhard | Marcus Jakob | Stefanie E Tüchert | S. Tüchert
[1] Thomas E. Hughes,et al. Pembrolizumab and decitabine for refractory or relapsed acute myeloid leukemia , 2018, Journal for ImmunoTherapy of Cancer.
[2] Sandeep Kumar Dhanda,et al. Relevance of Molecular Groups in Children with Newly Diagnosed Atypical Teratoid Rhabdoid Tumor: Results from Prospective St. Jude Multi-institutional Trials , 2021, Clinical Cancer Research.
[3] S. Bens,et al. Clinical and genetic risk factors define two risk groups of extracranial malignant rhabdoid tumours (eMRT/RTK). , 2020, European journal of cancer.
[4] M. Kool,et al. Molecular subgrouping of atypical teratoid/rhabdoid tumors—a reinvestigation and current consensus , 2019, Neuro-oncology.
[5] S. Bens,et al. Age and DNA-methylation subgroup as potential independent risk factors for treatment stratification in children with Atypical Teratoid/Rhabdoid Tumors (ATRT). , 2019, Neuro-oncology.
[6] J. Gerss,et al. Macrophage-tumor cell interaction promotes ATRT progression and chemoresistance , 2019, Acta Neuropathologica.
[7] D. Surdez,et al. Clonally Expanded T Cells Reveal Immunogenicity of Rhabdoid Tumors. , 2019, Cancer cell.
[8] Steven J. M. Jones,et al. Identification and Analyses of Extra-Cranial and Cranial Rhabdoid Tumor Molecular Subgroups Reveal Tumors with Cytotoxic T Cell Infiltration , 2019, Cell reports.
[9] P. Kearns,et al. Phase 1–2 safety, efficacy and pharmacokinetic study of decitabine in sequential administration with cytarabine in children with relapsed or refractory acute myeloid leukaemia , 2019, British journal of haematology.
[10] M. Brock,et al. Addition of Low-Dose Decitabine to Anti-PD-1 Antibody Camrelizumab in Relapsed/Refractory Classical Hodgkin Lymphoma. , 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[11] D. Teachey,et al. A Phase II Study of Alisertib in Children with Recurrent/Refractory Solid Tumors or Leukemia: Children's Oncology Group Phase I and Pilot Consortium (ADVL0921) , 2019, Clinical Cancer Research.
[12] M. Wildgruber,et al. The beginning of the end for conventional RECIST — novel therapies require novel imaging approaches , 2019, Nature Reviews Clinical Oncology.
[13] M. Brock,et al. Phase Ib/II study of safety and efficacy of low‐dose decitabine‐primed chemoimmunotherapy in patients with drug‐resistant relapsed/refractory alimentary tract cancer , 2018, International journal of cancer.
[14] M. Frühwald,et al. Emerging therapeutic targets for the treatment of malignant rhabdoid tumors , 2018, Expert opinion on therapeutic targets.
[15] Till Acker,et al. DNA methylation-based classification of central nervous system tumours , 2018, Nature.
[16] Rare Tumors in Kids May Respond to Tazemetostat. , 2018, Cancer discovery.
[17] N. André,et al. Sustained Complete Response to Metronomic Chemotherapy in a Child with Refractory Atypical Teratoid Rhabdoid Tumor: A Case Report , 2017, Front. Pharmacol..
[18] D. Eslin,et al. Epigenetic Combination Therapy for Children With Secondary Myelodysplastic Syndrome (MDS)/Acute Myeloid Leukemia (AML) and Concurrent Solid Tumor Relapse. , 2017, Journal of pediatric hematology/oncology.
[19] K. Oetjen,et al. Immunological effects of hypomethylating agents , 2017, Expert review of hematology.
[20] N. Penel,et al. irRECIST and iRECIST: the devil is in the details. , 2017, Annals of oncology : official journal of the European Society for Medical Oncology.
[21] Jason E. Farrar,et al. A multicenter, randomized study of decitabine as epigenetic priming with induction chemotherapy in children with AML , 2017, bioRxiv.
[22] M. Fischer,et al. A Phase I Study of the CDK4/6 Inhibitor Ribociclib (LEE011) in Pediatric Patients with Malignant Rhabdoid Tumors, Neuroblastoma, and Other Solid Tumors , 2017, Clinical Cancer Research.
[23] M. Beckmann,et al. Inhibiting DNA Methylation Causes an Interferon Response in Cancer via dsRNA Including Endogenous Retroviruses , 2017, Cell.
[24] Robert Ford,et al. iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics. , 2017, The Lancet. Oncology.
[25] A. King,et al. Assessment of the treatment approach and survival outcomes in a modern cohort of patients with atypical teratoid rhabdoid tumors using the National Cancer Database , 2017, Cancer.
[26] L. Schwartz,et al. High rate of complete responses to immune checkpoint inhibitors in patients with relapsed or refractory Hodgkin lymphoma previously exposed to epigenetic therapy , 2016, Journal of Hematology & Oncology.
[27] M. Prados,et al. Inhibition of DNA damage repair by the CDK4/6 inhibitor palbociclib delays irradiated intracranial atypical teratoid rhabdoid tumor and glioblastoma xenograft regrowth. , 2016, Neuro-oncology.
[28] David T. W. Jones,et al. Next-generation personalised medicine for high-risk paediatric cancer patients - The INFORM pilot study. , 2016, European journal of cancer.
[29] Mei Lu,et al. Integrated (epi)-Genomic Analyses Identify Subgroup-Specific Therapeutic Targets in CNS Rhabdoid Tumors. , 2016, Cancer cell.
[30] C. Roberts,et al. Atypical teratoid/rhabdoid tumors-current concepts, advances in biology, and potential future therapies. , 2016, Neuro-oncology.
[31] R. Siebert,et al. Improved 6‐year overall survival in AT/RT – results of the registry study Rhabdoid 2007 , 2016, Cancer medicine.
[32] W. Han,et al. DNA demethylating agent decitabine broadens the peripheral T cell receptor repertoire , 2016, Oncotarget.
[33] Steven J. M. Jones,et al. Genome-Wide Profiles of Extra-cranial Malignant Rhabdoid Tumors Reveal Heterogeneity and Dysregulated Developmental Pathways. , 2016, Cancer cell.
[34] Roland Eils,et al. Atypical Teratoid/Rhabdoid Tumors Are Comprised of Three Epigenetic Subgroups with Distinct Enhancer Landscapes. , 2016, Cancer cell.
[35] P. Cabrales,et al. Partial Response to Platinum Doublets in Refractory EGFR-Positive Non-Small Cell Lung Cancer Patients after RRx-001: Evidence of Episensitization , 2016, Case Reports in Oncology.
[36] A. Koch,et al. Long-term survival of an infant with an atypical teratoid/rhabdoid tumor following subtotal resection and low-cumulative dose chemotherapy: a case report , 2016, Child's Nervous System.
[37] D. Matei,et al. Carboplatin with Decitabine Therapy, in Recurrent Platinum Resistant Ovarian Cancer, Alters Circulating miRNAs Concentrations: A Pilot Study , 2015, PloS one.
[38] Xin Hu,et al. Epigenetic synergy between decitabine and platinum derivatives , 2015, Clinical Epigenetics.
[39] Trevor J Pugh,et al. DNA-Demethylating Agents Target Colorectal Cancer Cells by Inducing Viral Mimicry by Endogenous Transcripts , 2015, Cell.
[40] L. Diller,et al. A phase I trial combining decitabine/dendritic cell vaccine targeting MAGE-A1, MAGE-A3 and NY-ESO-1 for children with relapsed or therapy-refractory neuroblastoma and sarcoma , 2015, Cancer Immunology, Immunotherapy.
[41] R. Day,et al. Episensitization: Defying Time’s Arrow , 2015, Front. Oncol..
[42] Martin Bendszus,et al. Response assessment criteria for brain metastases: proposal from the RANO group. , 2015, The Lancet. Oncology.
[43] C. Wetmore,et al. Alisertib is active as single agent in recurrent atypical teratoid rhabdoid tumors in 4 children. , 2015, Neuro-oncology.
[44] M. Massimino,et al. A case of relapsing spinal atypical teratoid/rhabdoid tumor (AT/RT) responding to vinorelbine, cyclophosphamide, and celecoxib , 2015, Child's Nervous System.
[45] Gary D Bader,et al. Molecular subgroups of atypical teratoid rhabdoid tumours in children: an integrated genomic and clinicopathological analysis. , 2015, The Lancet. Oncology.
[46] S. Fulda,et al. RIST: A potent new combination therapy for glioblastoma , 2015, International journal of cancer.
[47] T. Athanasiou,et al. Multimodal therapy in children and adolescents with newly diagnosed atypical teratoid rhabdoid tumor: individual pooled data analysis and review of the literature , 2015, Journal of Neuro-Oncology.
[48] H. Kantarjian,et al. Safety and clinical activity of 5‐aza‐2′‐deoxycytidine (decitabine) with or without Hyper‐CVAD in relapsed/refractory acute lymphocytic leukaemia , 2014, British journal of haematology.
[49] M. Kool,et al. Arsenic trioxide inhibits tumor cell growth in malignant rhabdoid tumors in vitro and in vivo by targeting overexpressed Gli1 , 2014, International journal of cancer.
[50] R. Siebert,et al. SMARCA4-mutated atypical teratoid/rhabdoid tumors are associated with inherited germline alterations and poor prognosis , 2014, Acta Neuropathologica.
[51] D. Matei,et al. Decitabine reactivated pathways in platinum resistant ovarian cancer , 2014, Oncotarget.
[52] B. Geoerger,et al. Phase II study of irinotecan in combination with temozolomide (TEMIRI) in children with recurrent or refractory medulloblastoma: a joint ITCC and SIOPE brain tumor study. , 2013, Neuro-oncology.
[53] R. Garzon,et al. Low dose decitabine in very high risk relapsed or refractory acute myeloid leukaemia in children and young adults , 2013, British journal of haematology.
[54] V. Marquez,et al. Inhibition of EZH2 suppresses self-renewal and induces radiation sensitivity in atypical rhabdoid teratoid tumor cells. , 2013, Neuro-oncology.
[55] D. Krishnadas,et al. Complete Remission Following Decitabine/Dendritic Cell Vaccine for Relapsed Neuroblastoma , 2013, Pediatrics.
[56] L. Garraway,et al. Absence of oncogenic canonical pathway mutations in aggressive pediatric rhabdoid tumors , 2012, Pediatric blood & cancer.
[57] M. Minden,et al. Multicenter, randomized, open-label, phase III trial of decitabine versus patient choice, with physician advice, of either supportive care or low-dose cytarabine for the treatment of older patients with newly diagnosed acute myeloid leukemia. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[58] D. Matei,et al. Epigenetic resensitization to platinum in ovarian cancer. , 2012, Cancer research.
[59] D. Johnston,et al. Central nervous system atypical teratoid rhabdoid tumours: the Canadian Paediatric Brain Tumour Consortium experience. , 2012, European journal of cancer.
[60] R. Vibhakar,et al. Targeting Aurora Kinase A enhances radiation sensitivity of atypical teratoid rhabdoid tumor cells , 2012, Journal of Neuro-Oncology.
[61] D. Zagzag,et al. Aurora A is a repressed effector target of the chromatin remodeling protein INI1/hSNF5 required for rhabdoid tumor cell survival. , 2011, Cancer research.
[62] J. Biegel,et al. Spectrum of SMARCB1/INI1 mutations in familial and sporadic rhabdoid tumors , 2011, Pediatric blood & cancer.
[63] D. Neuberg,et al. Phase I study of decitabine with doxorubicin and cyclophosphamide in children with neuroblastoma and other solid tumors: A children's oncology group study , 2010, Pediatric blood & cancer.
[64] R. Siebert,et al. Germline nonsense mutation and somatic inactivation of SMARCA4/BRG1 in a family with rhabdoid tumor predisposition syndrome. , 2010, American journal of human genetics.
[65] R. Barr,et al. Childhood Atypical Teratoid Rhabdoid Tumor of the Central Nervous System: A Meta-Analysis of Observational Studies , 2009, Journal of pediatric hematology/oncology.
[66] J. Biegel,et al. Intensive multimodality treatment for children with newly diagnosed CNS atypical teratoid rhabdoid tumor. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[67] F. Lyko,et al. Modes of action of the DNA methyltransferase inhibitors azacytidine and decitabine , 2008, International journal of cancer.
[68] Andreas Schätzlein,et al. Phase I and pharmacodynamic trial of the DNA methyltransferase inhibitor decitabine and carboplatin in solid tumors. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[69] John M Bennett,et al. Decitabine improves patient outcomes in myelodysplastic syndromes , 2006, Cancer.
[70] Amanda J. Thomas,et al. A Feasibility Trial of Antiangiogenic (Metronomic) Chemotherapy in Pediatric Patients With Recurrent or Progressive Cancer , 2005, Journal of pediatric hematology/oncology.
[71] J. Sludden,et al. Reversal of drug resistance in human tumor xenografts by 2'-deoxy-5-azacytidine-induced demethylation of the hMLH1 gene promoter. , 2000, Cancer research.
[72] G. Rivard,et al. Plasma and cerebrospinal fluid pharmacokinetics of 5-Aza-2'-deoxycytidine in rabbits and dogs. , 1983, Cancer research.